Skip to main content
SpringerLink
Log in

Krebs und Hormone

  • Chapter
Die Gynäkologie

  • 14k Accesses

Zusammenfassung

Hormone sind für Entstehung, Wachstum und Therapie vieler gynäkologischer Malignome von großer Bedeutung. Die Wechselwirkungen zwischen Östrogenen und Progestagenen spielen für die Karzinogenese in Endometrium und Brust eine wichtige Rolle. Dies gilt auch für Androgene, da sie in Östrogene metabolisiert werden können.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 199.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Anderson GL, Judd HL, Kaunitz AM, Barad DH, Beresford SA, Pettinger M, Liu J, McNeeley SG, Lopez AM; Women's Health Initiative Investigators (2003) Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA 290 (13): 1739–1748

    Google Scholar 

  • Anderson GL, Limacher M, Assaf AR et al. (2004) Effects of conjugated equine estrogen in post menopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 14: 1701–1712

    Google Scholar 

  • Antoine C, Liebens F, Carly B, Pastijn A, Neusy S, Rozenberg S (2007) Safety of hormone therapy after breast cancer: a qualitative systematic review. Hum Reprod 22 (2): 616–22

    Article  PubMed  CAS  Google Scholar 

  • Beral V; Million Women Study Collaborators (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362 (9382): 419–427

    Google Scholar 

  • Beral V, Bull D, Reeves G (2005) Endometrial cancer and hormonereplacement therapy in the Million Women Study. Lancet. 9470: 1543–1551

    Google Scholar 

  • Booth M, Beral V, Smith P (1989) Risk factors for ovarian cancer: a casecontrol study. Br J Cancer 60: 592

    Article  PubMed  CAS  Google Scholar 

  • Brinton LA, Westhoff CL, Scoccia B et al. (2005) Causes of infertility as predictors of subsequent cancer risk. Epidemiology 4: 500–507

    Article  Google Scholar 

  • Chakravarty D, Srinivasan R, Ghosh S et al. (2007) Estrogen receptor beta1 and the beta2/betacx isoforms in nonneoplastic endometrium and in endometrioid carcinoma. Int J Gynecol Cancer 17: 905–913

    Article  PubMed  CAS  Google Scholar 

  • Chan KK, Wei N, Liu SS, Xiao-Yun L, Cheung AN, Ngan HY (2008) Estrogen receptor subtypes in ovarian cancer: a clinical correlation. Obstet Gynecol 111: 144

    Article  PubMed  CAS  Google Scholar 

  • Chang M (2011) Dual roles of estrogen metabolism in mammary carcinogenesis. BMB Rep 44 (7): 423–434

    Article  PubMed  CAS  Google Scholar 

  • Cherry N, Gilmour K, Hannaford P, Heagarty A, Khan MA, Kitchener HC, McNamee R, Elstein M, Kay C, Seif M (2002) Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet 360: 2001–2008

    Article  PubMed  CAS  Google Scholar 

  • Chlebowski RT, Hendrix SL, Lander RD, Stefanick ML, Gass MLS, Lane DS, Rodabough RJ, Gilligan A, Cyr MG, Thomson CA (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. JAMA 289: 3243– 3253

    Article  PubMed  CAS  Google Scholar 

  • Clemons M, Goss P (2001) Estrogen and the risk of breast cancer. N Engl J Med 344: 276

    Article  PubMed  CAS  Google Scholar 

  • Col NF, Kim JA, Chlebowski RT (2005) Menopausal hormone therapy after breast cancer: a meta-analysis and critical appraisal of the evidence. Breast Cancer Res 7 (4): R535–540

    Article  PubMed  CAS  Google Scholar 

  • Collaborative Group on Epidemiological Studies of Ovarian Cancer (2008) Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23257 women with ovarian cancer and 87303 controls. Lancet 371: 303

    Google Scholar 

  • Collaborative Group on Hormonal Factors in Breast Cancer (1996) Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53, 297 women with breast cancer and 100, 239 women without breast cancer from 54 epidemiological studies. Lancet 347: 1713

    Google Scholar 

  • Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52, 705 women with breast cancer and 108, 411 women without breast cancer. Lancet 350: 1047

    Google Scholar 

  • Collins JA, Blake JM, Crosignani PG (2005a) Breast cancer risk with postmenopausal hormonal treatment. Hum Reprod Update 6: 545–560

    Article  Google Scholar 

  • Collins JA, Blake JM, Crosignani PG (2005b) Breast cancer risk with postmenopausal hormonal treatment. Hum Reprod Update 11: 545–560

    Article  CAS  Google Scholar 

  • Doherty JA, Cushing-Haugen KL, Saltzman BS, Voigt LF, Hill DA, Beresford SA, Chen C, Weiss NS (2007) Long-term use of postmenopausal estrogen and progestin hormone therapies and the risk of endometrial cancer. Am J Obstet Gynecol 197 (2): 139.e1–7

    Article  Google Scholar 

  • Eeles RA, Tan S, Wiltshaw E et al. (1991) Hormone replacement therapy and survival after surgery for ovarian cancer. BMJ 302: 259

    Article  PubMed  CAS  Google Scholar 

  • Ehrlich CE, Young PC, Cleary RE (1981) Cytoplasmic progesterone and estradiol receptors in normal, hyperplastic, and carcinomatous endometria: therapeutic implications. Am J Obstet Gynecol 141: 539

    PubMed  CAS  Google Scholar 

  • Farquhar CM, Marjoribanks J, Lethaby A, Lamberts Q, Suckling JA, and the Cochrane HT Study Group (2008) Long-term hormone therapy for perimenopausal and postmenopausal women (Review). Cochrane Database of Systematic Reviews 2005, issue 3, CD004143 und Long-term hormone therapy for perimenopausal and postmenopausal women (Review). New search for studies completed, conclusions not changed. The Cochrane Library Issue 4

    Google Scholar 

  • Greiser CM, Greiser EM, Dören M (2005) Menopausal hormone therapy and risk of breast cancer: a meta-analysis of epidemiological studies and randomized controlled trials. Hum Reprod Update 11: 561–573

    Article  PubMed  CAS  Google Scholar 

  • Greiser CM, Greiser EM, Dören M (2007) Menopausal hormone therapy and risk of ovarian cancer: systematic review and meta-analysis. Hum Reprod Update 13 (5): 453–463

    Article  PubMed  CAS  Google Scholar 

  • Hanekamp EE, Gielen SC, Smid-Koopman E et al. (2003) Consequences of loss of progesterone receptor expression in development of invasive endometrial cancer. Clin Cancer Res 9: 4190

    PubMed  CAS  Google Scholar 

  • Henderson BE, Casagrande JT, Pike MC et al. (1983) The epidemiology of endometrial cancer in young women. Br J Cancer 47: 749

    Article  PubMed  CAS  Google Scholar 

  • Hodis HN, Mack WJ, Lobo RA, Shoupe D, Sevanian A, Mahrer PR, Selzer RH, Liu CR, Liu CH, Azen SP (2001) Estrogen in the prevention of atherosclerosis: a randomized, double-blind, placebocontrolled trial. Ann Intern Med 135: 939–953

    PubMed  CAS  Google Scholar 

  • Holmberg L, Iversen OE, Rudenstam CM, Hammar M, Kumpulainen E, Jaskiewicz J, Jassem J, Dobaczewska D, Fjosne HE, Peralta O, Arriagada R, Holmqvist M, Maenpaa J; HABITS Study Group (2008) Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst 100 (7): 475–482

    Google Scholar 

  • Hulley S, Furberg C, Barrett-Connor E et al. (2002) Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 1: 58–66

    Article  Google Scholar 

  • Hunt K, Vessey M, McPherson K, Coleman M (1987) Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. Br J Obstet Gynaecol 94 (7): 620– 635

    Article  PubMed  CAS  Google Scholar 

  • IARC Working Group on the Evaluation of Carcinogenic Risks to Humans (2007) Combined estrogen-progestogen contraceptives and combined estrogen-progestogen menopausal therapy. IARC Monogr Eval Carcinog Risks Hum 91: 1–528

    Google Scholar 

  • Ito K, Utsunomiya H, Yaegashi N, Sasano H (2007) Biological roles of estrogen and progesterone in human endometrial carcinoma –new developments in potential endocrine therapy for endometrial cancer. Endocr J 54: 667

    Article  PubMed  CAS  Google Scholar 

  • Kashyap S, Moher D, Fung MF et al. (2004) Assisted reproductive technology and the incidence of ovarian cancer: a meta-analysis. Obstet Gynecol 4: 785–794

    Article  Google Scholar 

  • Kenemans P, Bundred NJ, Foidart JM, Kubista E, von Schoultz B, Sismondi P, Vassilopoulou-Sellin R, Yip CH, Egberts J, Mol-Arts M, Mulder R, van Os S, Beckmann MW; LIBERATE Study Group (2009) Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol 10 (2): 135–146

    Google Scholar 

  • Kumar SR, Masood R, Spannuth WA et al. (2007) The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome. Br J Cancer 96: 1083

    Article  PubMed  CAS  Google Scholar 

  • Landis SH, Murray T, Bolden S, Wingo PA (1999) Cancer statistics, 1999. CA Cancer J Clin 49: 8

    Article  PubMed  CAS  Google Scholar 

  • Lee SA, Ross RK, Pike MC (2005) An overview of menopausal oestrogenprogestin hormone therapy and breast cancer risk. Br J Cancer 92: 2049–2058

    Article  PubMed  CAS  Google Scholar 

  • Li CI, Malone KE, Daling JR (2006) Interactions between body mass index and hormone therapy and postmenopausal breast cancer risk (United States). Cancer Causes Control 17: 695

    Article  PubMed  Google Scholar 

  • Lin CY, Ström A, Li Kong S et al. (2007) Inhibitory effects of estrogen receptor beta on specific hormone-responsive gene expression and association with disease outcome in primary breast cancer. Breast Cancer Res 9: R25

    Article  PubMed  Google Scholar 

  • Lucenteforte E, Bosetti C, Talamini R et al. (2007) Diabetes and endometrial cancer: effect modification by body weight, physical activity and hypertension. Br J Cancer 97: 995

    Article  PubMed  CAS  Google Scholar 

  • MacMahon B (1974) Risk factors for endometrial cancer. Gynecol Oncol 2: 122

    Article  PubMed  CAS  Google Scholar 

  • Mant JW, Vessey MP (1994) Ovarian and endometrial cancers. Cancer Surv 287: 19

    Google Scholar 

  • McMichael AJ, Potter JD (1980) Reproduction, endogenous and exogenous sex hormones, and colon cancer: a review and hypothesis. JNCI 65: 1201

    PubMed  CAS  Google Scholar 

  • Mignogna MD, Fedele S, Lo Russo L (2004) The World Cancer Report and the burden of oral cancer. Eur J Cancer Prev 2: 139–142

    Article  Google Scholar 

  • Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE (2004) Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst 96 (24): 1856–1865

    Article  PubMed  CAS  Google Scholar 

  • Narod SA, Risch H, Moslehi R et al. (1998) Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 339: 424

    Article  PubMed  CAS  Google Scholar 

  • Newton KM, Reed SD, LaCroix AZ, Grothaus LC, Ehrlich K, Guiltinan J (2006) Treatment of Vasomotor Symptoms of Menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo. Ann Intern Med 145: 869–879

    PubMed  Google Scholar 

  • Ortmann O, König K (2005) Hormontherapie im Klimakterium und in der Postmenopause. Dtsch Ärztebl 3: A144–147

    Google Scholar 

  • Ortmann O, Schulz KD, Diedrich K (2000) Hormonersatztherapie in der Postmenopause und Mammakarzinomrisiko. Gynäkologe 33: 402

    Article  Google Scholar 

  • Ortmann O, Diedrich K, Emons G, Felberbaum R, van der Ven H (2008) Ovarielle Stimulationsbehandlungen und Ovarialkarzinomrisiko. Frauenarzt 1: 16–18

    Google Scholar 

  • Park BW, Kim KS, Heo MK et al. (2006) The changes of estrogen receptor- beta variants expression in breast carcinogenesis: Decrease of estrogen receptor-beta2 expression is the key event in breast cancer development. J Surg Oncol 93: 504

    Article  PubMed  CAS  Google Scholar 

  • Risch HA, Marrett LD, Howe GR (1994) Parity, contraception, infertility, and the risk of epithelial ovarian cancer. Am J Epidemiol 140: 585

    PubMed  CAS  Google Scholar 

  • Ron E, Lunenfeld B, Menczer J et al. (1987) Cancer incidence in a cohort of infertile women. Am J Epidemiol 125: 780

    PubMed  CAS  Google Scholar 

  • Rossing MA, Daling JR, Weiss NS et al. (1994) Ovarian tumors in a cohort of infertile women. N Engl J Med 331: 771

    Article  PubMed  CAS  Google Scholar 

  • Rossouw JE, Anderson GL, Prentice RL et al. (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288: 321–333

    Article  PubMed  CAS  Google Scholar 

  • Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women's Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288 (3): 321–33

    Google Scholar 

  • Rushton L, Jones DR (1992) Oral contraceptive use and breast cancer risk: a meta-analysis of variations with age at diagnosis, parity and total duration of oral contraceptive use. Br J Obstet Gynaecol 3: 239–246

    Google Scholar 

  • Santen RJ (2003) Risk of breast cancer with progestins: critical assessment of current data. Steroids 68 (10-13): 953–964

    Article  PubMed  CAS  Google Scholar 

  • Santen RJ, Song RX, Zhang Z, Kumar R, Jeng MH, Masamura A, Lawrence J Jr, Berstein L, Yue W (2005) Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity. Endocr Relat Cancer 12 Suppl 1: S61–73

    Article  PubMed  CAS  Google Scholar 

  • Schultze-Mosgau A, Ortmann O, Diedrich K (2002) Wirkungen von Tamoxifen auf das Endometrium. Geburtsh Frauenheilkd 62: 743

    Article  Google Scholar 

  • Shah NR, Borenstein J, Dubois RW (2005) Postmenopausal hormone therapy and breast cancer: a systematic review and meta-analysis. Menopause 12: 668–678

    Article  PubMed  Google Scholar 

  • Sugiura H, Toyama T, Hara Y, Zhang Z, Kobayashi S, Fujii Y, Iwase H, Yamashita H (2007) Expression of estrogen receptor beta wildtype and its variant ERbetacx/beta2 is correlated with better prognosis in breast cancer. Jpn J Clin Oncol 37 (11): 820–828

    Article  PubMed  Google Scholar 

  • Treeck O, Pfeiler G, Mitter D et al. (2007) Estrogen receptor β1 exerts antitumoral effects on SK-OV-3 ovarian cancer cells. J Endocrinol 193: 421

    Article  PubMed  CAS  Google Scholar 

  • Vessey MP, Painter R (1995) Endometrial and ovarian cancer and oral contraceptives – findings in a large cohort study. Br J Cancer 71: 1340

    Article  PubMed  CAS  Google Scholar 

  • Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI (2001) A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 345: 1243–1249

    Article  PubMed  CAS  Google Scholar 

  • Weiss NS, Szekely DR, Austin DF (1976) Increasing incidence of endometrial cancer in the United States. N Engl J Med 294: 1259

    Article  PubMed  CAS  Google Scholar 

  • Williams C, Edvardsson K, Lewandowski SA, Ström A, Gustafsson JA (2008) A genome-wide study of the repressive effects of estrogen receptor beta on estrogen receptor alpha signaling in breast cancer cells. Oncogene 27: 1019–1032

    Article  PubMed  CAS  Google Scholar 

  • Zhang H, Yee D (2006) Is the type I insulin-like growth factor receptor a therapeutic target in endometrial cancer? Clin Cancer Res 12: 6323

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Frauenheilkunde und Geburtshilfe der Universität, Regensburg am Caritas-Krankenhaus St. Josef, Landshuter Straße 65, 93053, Regensburg

    Dr. med. D. Noss & Prof. Dr. med. O. Ortmann

Authors
  1. Dr. med. D. Noss
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. O. Ortmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Johann-Wolfgang-Goethe-Universität Frankfurt, Universitätsfrauenklinik, Frankfurt

    Manfred Kaufmann

  2. Otto-von-Guericke-Universität Magdeburg, Universitätsfrauenklinik, Magdeburg

    Serban D. Costa

  3. Friedrich-Alexander-Universität Erlangen-Nürnberg, Klinikum St. Marien, Lehrkrankenhaus der Universität Regensburg, Erlangen-Nürnberg

    Anton Scharl

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Noss, D., Ortmann, O. (2013). Krebs und Hormone. In: Kaufmann, M., Costa, S.D., Scharl, A. (eds) Die Gynäkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-20923-9_36

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-20923-9_36

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-20922-2

  • Online ISBN: 978-3-642-20923-9

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation